96 related articles for article (PubMed ID: 10443689)
1. Phenylacetate inhibits growth and vascular endothelial growth factor secretion in human thyroid carcinoma cells and modulates their differentiated function.
Kebebew E; Wong MG; Siperstein AE; Duh QY; Clark OH
J Clin Endocrinol Metab; 1999 Aug; 84(8):2840-7. PubMed ID: 10443689
[TBL] [Abstract][Full Text] [Related]
2. Phenylacetate enhances the antiproliferative effect of retinoic acid in follicular thyroid cancer.
Eigelberger MS; Wong MG; Duh QY; Clark OH
Surgery; 2001 Dec; 130(6):931-5. PubMed ID: 11742319
[TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid.
Soh EY; Duh QY; Sobhi SA; Young DM; Epstein HD; Wong MG; Garcia YK; Min YD; Grossman RF; Siperstein AE; Clark OH
J Clin Endocrinol Metab; 1997 Nov; 82(11):3741-7. PubMed ID: 9360534
[TBL] [Abstract][Full Text] [Related]
4. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
Tuttle RM; Fleisher M; Francis GL; Robbins RJ
J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of thyroid stimulating hormone in a differentiated thyroid cancer cell line. Studies on proliferation, thyroglobulin secretion, adhesion, migration and invasion.
Zielke A; Hoffmann S; Plaul U; Duh QY; Clark OH; Rothmund M
Exp Clin Endocrinol Diabetes; 1999; 107(6):361-9. PubMed ID: 10543413
[TBL] [Abstract][Full Text] [Related]
6. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
[TBL] [Abstract][Full Text] [Related]
7. Phenylacetate inhibits isoprenoid biosynthesis and suppresses growth of human pancreatic carcinoma.
Harrison LE; Wojciechowicz DC; Brennan MF; Paty PB
Surgery; 1998 Sep; 124(3):541-50. PubMed ID: 9736908
[TBL] [Abstract][Full Text] [Related]
8. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
Belletti B; Ferraro P; Arra C; Baldassarre G; Bruni P; Staibano S; De Rosa G; Salvatore G; Fusco A; Persico MG; Viglietto G
Oncogene; 1999 Aug; 18(34):4860-9. PubMed ID: 10490819
[TBL] [Abstract][Full Text] [Related]
9. Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects.
Feldkamp MM; Lau N; Guha A
Oncogene; 1999 Dec; 18(52):7514-26. PubMed ID: 10602510
[TBL] [Abstract][Full Text] [Related]
10. Antiangiogenic and antitumor effects of endostatin on follicular thyroid carcinoma.
Ye C; Feng C; Wang S; Liu X; Lin Y; Li M
Endocrinology; 2002 Sep; 143(9):3522-8. PubMed ID: 12193566
[TBL] [Abstract][Full Text] [Related]
11. A new phenylacetate-bisphosphonate inhibits breast cancer cell growth by proapoptotic and antiangiogenic effects.
Sebbah-Louriki M; Colombo BM; el Manouni D; Martin A; Salzmann JL; Leroux Y; Perret GY; Crépin M
Anticancer Res; 2002; 22(6C):3925-31. PubMed ID: 12553014
[TBL] [Abstract][Full Text] [Related]
12. Tumor necrosis factor alpha induces three-dimensional cytomorphologic differentiation of human anaplastic thyroid carcinoma cells through activation of nuclear factor kappaB.
Wang CY; Zhong WB; Chang TC; Lai SM; Tsai YF
Cancer; 2002 Nov; 95(9):1827-33. PubMed ID: 12404274
[TBL] [Abstract][Full Text] [Related]
13. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
[TBL] [Abstract][Full Text] [Related]
14. Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia.
Ebos JM; Tran J; Master Z; Dumont D; Melo JV; Buchdunger E; Kerbel RS
Mol Cancer Res; 2002 Dec; 1(2):89-95. PubMed ID: 12496355
[TBL] [Abstract][Full Text] [Related]
15. Potentiation of the antiangiogenic ability of linomide by androgen ablation involves down-regulation of vascular endothelial growth factor in human androgen-responsive prostatic cancers.
Joseph IB; Isaacs JT
Cancer Res; 1997 Mar; 57(6):1054-7. PubMed ID: 9067270
[TBL] [Abstract][Full Text] [Related]
16. Recombinant human thyrotropin reduces serum vascular endothelial growth factor levels in patients monitored for thyroid carcinoma even in the absence of thyroid tissue.
Sorvillo F; Mazziotti G; Carbone A; Piscopo M; Rotondi M; Cioffi M; Musto P; Biondi B; Iorio S; Amato G; Carella C
J Clin Endocrinol Metab; 2003 Oct; 88(10):4818-22. PubMed ID: 14557460
[TBL] [Abstract][Full Text] [Related]
17. Metformin inhibits growth of thyroid carcinoma cells, suppresses self-renewal of derived cancer stem cells, and potentiates the effect of chemotherapeutic agents.
Chen G; Xu S; Renko K; Derwahl M
J Clin Endocrinol Metab; 2012 Apr; 97(4):E510-20. PubMed ID: 22278418
[TBL] [Abstract][Full Text] [Related]
18. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo.
Antonelli A; Bocci G; La Motta C; Ferrari SM; Fallahi P; Ruffilli I; Di Domenicantonio A; Fioravanti A; Sartini S; Minuto M; Piaggi S; Corti A; Alì G; Di Desidero T; Berti P; Fontanini G; Danesi R; Da Settimo F; Miccoli P
J Clin Endocrinol Metab; 2012 Apr; 97(4):E528-36. PubMed ID: 22278419
[TBL] [Abstract][Full Text] [Related]
19. Retinoic acid inhibits angiogenesis and tumor growth of thyroid cancer cells.
Hoffmann S; Rockenstein A; Ramaswamy A; Celik I; Wunderlich A; Lingelbach S; Hofbauer LC; Zielke A
Mol Cell Endocrinol; 2007 Jan; 264(1-2):74-81. PubMed ID: 17101211
[TBL] [Abstract][Full Text] [Related]
20. Phenylacetate inhibits growth and modulates cell cycle gene expression in renal cancer cell lines.
Franco OE; Onishi T; Umeda Y; Soga N; Wakita T; Arima K; Yanagawa M; Sugimura Y
Anticancer Res; 2003; 23(2B):1637-42. PubMed ID: 12820434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
